PATENT CLAIM ANALYSIS

Application Number: 16234364
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-06
Patent Classification: ["514", "211000"]

Abstract:
The present invention relates to crystal modifications of N-{(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,5-benzothiazepin-8-yl]oxy}acetyl)amino]-2-phenylethanolyl}glycine (elobixibat).

Claim (Index 7):
A method for the treatment of non-alcoholic fatty liver disease (NAFLD), the method comprising administering to the subject a therapeutically effective amount of the crystalline form of  claim 2 .

Metadata:
- Claim Count in Document: 41.0
- Percentile: 98.0
- Lexical Diversity: 1.37037
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15519808', '15134583', '15134586', '14429388', '15925270']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7203673498270661
- 35 USC 102 Novelty (BERT): 0.618974773740669
- Combined Prediction Score: 0.7102280922184264
- Mean Citation Score: 364.651854
- Max Citation Score: 534.8228
- Similarity Product: 526.569031929636

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test